Endocrine Abstracts

Toxic hepatitis is a diffuse inflammatory process in the liver which is caused by the impact of industrial poisons of hepatotoxic action in doses exceeding the maximum allowable concentration. Given the complexity of differentiation, in fact, the symptoms of the disease from possible side effects of treatment, the statistics of the prevalence of the disease in this profile is quite ambiguous. Data from clinical studies show that in the structure of acute and chronic liver disease the drug lesions range from 0.7% to 20% and the percentage of all adverse reactions associated with the use of drugs ranges from 2% to 28%, 10% of which are cytostatic.

Aim: Of the work is to improve the possibility of diagnosing liver fibrosis due to its toxic lesion after chemotherapy in patients with normal weight and overweight by analyzing serum markers of fibrosis.

Materials and Methods: In dynamics, 88 people aged from 31 to 74 years with toxic liver damage without symptoms of cirrhosis and concurrent pathology of the liver and biliary tract were studied.

Results: All subjects were female (100%). The Fibrotest method was used to diagnose the stages of liver fibrosis. Analyzing the level of profibrogenic cytokine TGF-β ₁ it was noted that the lowest value was 6123 ng/ml, the highest level was noted at 19746 ng/ml, with the average value for all examined patients was 12758 ± 3518.3. It was found to increase significantly with increasing stage of fibrosis and BMI with maximum values in the group of patients with toxic liver disease and obese. With the progression of liver fibrosis, the concentration of TGF-β₁ (r=0.83, P<0.05) in the blood increases, which confirms the role of TGF-β₁ in the activation of liver stellate cells and stimulation of collagen and other extracellular matrix synthesis and is likely a marker of the progression of fibrosing reactions. Also, direct strong correlations of TFG-β ₁ with the stage of liver fibrosis according to the fibrotest (r=0.88, P<0.05).

Conclusions: The presence of excess body weight in cancer patients in stable remission correlates with the severity of liver fibrosis and may be an important factor in predicting the development of severe fibrosis in patients in the long term due to breast cancer treatment. The level of profibrogenic cytokine TFG β₁ correlates with the severity of liver fibrosis according to fibrotest and may be a sensitive predictor of fibrosis progression.